PL378247A1 - Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych - Google Patents

Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych

Info

Publication number
PL378247A1
PL378247A1 PL378247A PL37824704A PL378247A1 PL 378247 A1 PL378247 A1 PL 378247A1 PL 378247 A PL378247 A PL 378247A PL 37824704 A PL37824704 A PL 37824704A PL 378247 A1 PL378247 A1 PL 378247A1
Authority
PL
Poland
Prior art keywords
neoplasms
treatment
lymphoid cells
pde4 inhibitors
pde4
Prior art date
Application number
PL378247A
Other languages
English (en)
Inventor
Jürgen Braunger
Christian Schudt
Armin Hatzelmann
Hermann Tenor
Volker Gekeler
Karl Sanders
Enrico Garattini
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PL378247A1 publication Critical patent/PL378247A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL378247A 2003-01-14 2004-01-14 Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych PL378247A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03000787 2003-01-14

Publications (1)

Publication Number Publication Date
PL378247A1 true PL378247A1 (pl) 2006-03-20

Family

ID=32695591

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378247A PL378247A1 (pl) 2003-01-14 2004-01-14 Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych

Country Status (10)

Country Link
US (1) US20060148804A1 (pl)
EP (1) EP1587512A2 (pl)
JP (1) JP2006515367A (pl)
AU (1) AU2004204355B2 (pl)
CA (1) CA2512819A1 (pl)
HR (1) HRP20050699A2 (pl)
IS (1) IS7970A (pl)
PL (1) PL378247A1 (pl)
RS (1) RS20050523A (pl)
WO (1) WO2004062671A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US20140112945A1 (en) * 2011-06-17 2014-04-24 Takeda Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
WO2013087749A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6047099A (en) * 1998-09-24 2000-04-10 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
US6232121B1 (en) * 1999-06-03 2001-05-15 Hugh S. Keeping Methods for the production of biologically active agents contained in an extracellular matrix
AU5195599A (en) * 1999-08-10 2001-03-13 Wago Co., Ltd. Anchor bolt and method of manufacturing the anchor bolt
HU229439B1 (hu) * 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
CA2388119A1 (en) * 1999-10-25 2001-05-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
WO2001093909A2 (en) * 2000-06-06 2001-12-13 Glaxo Group Limited Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor
HRP20030636B1 (en) * 2001-02-15 2012-05-31 Nycomed Gmbh Phthalayinone-piperidino-derivatives as pde4 inhibitors
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods

Also Published As

Publication number Publication date
RS20050523A (sr) 2007-09-21
WO2004062671A2 (en) 2004-07-29
WO2004062671A3 (en) 2005-01-27
US20060148804A1 (en) 2006-07-06
JP2006515367A (ja) 2006-05-25
AU2004204355B2 (en) 2009-12-17
EP1587512A2 (en) 2005-10-26
CA2512819A1 (en) 2004-07-29
HRP20050699A2 (en) 2006-11-30
IS7970A (is) 2005-08-05
AU2004204355A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
IL174232A0 (en) Combinations of drugs for the treatment of neoplasms
AU2003249244A1 (en) Methods for the treatment of neoplasms
PL373146A1 (pl) Pochodne pirydazynonu jako inhibitory PDE4
ZA200500618B (en) Combinations of drugs for the treatment of neoplasms
IL176028A0 (en) Compounds for treatment of cell proliferative diseases
EP1638508A4 (en) SHUNT FOR GLUCKOM TREATMENT
EP1664051A4 (en) PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USING SAME FOR TREATING PROLIFERATION DISORDERS
IL174014A0 (en) Methods for the treatment of endometriosis
GB2415378B (en) Treatment of neurodegenerative conditions
GB2422373B (en) Treatment of neurodegenerative conditions
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1651211A4 (en) COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF NEOPLASMS
AU2003251904A8 (en) Combinations of drugs for the treatment of neoplasms
PL378762A1 (pl) Leczenie nadmiernego zanikania rozpływnego kości związkami indolinonowymi
GB0419815D0 (en) Treatment of oily sludges
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
PL378247A1 (pl) Inhibitory PDE4 w terapii nowotworów komórek limfoidalnych
GB0424663D0 (en) Sludge treatment
GB0300783D0 (en) Treatment of neurodegenerative conditions
PL380068A1 (pl) Sposób obróbki szlamu
AU2003205452A8 (en) Bmp inhibitors for the treatment of spondyloarthropathies
PL1727545T3 (pl) Zastosowanie pochodnych N-piperydyny do leczenia patologii neurodegeneracyjnych
GB2422600B (en) Sludge treatment
GB0323078D0 (en) Sewage treatment
GB0327975D0 (en) Methods of treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)